Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTYXQF)

• Drug Name: NVP-AUY922 Drug Info
• Synonyms: Luminespib; 747412-49-3; AUY922; VER-52296; AUY-922; UNII-C6V1DAR5EB; AUY922 (NVP-AUY922); Luminespib (NVP-AUY922); NVP-AUY 922; 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide; C6V1DAR5EB; Luminespib (AUY-922, NVP-AUY922); CHEBI:83656; 5-[2,4-DIHYDROXY-5-ISOPROPYLPHENYL]-N-ETHYL-4-[4-(4-MORPHOLINYLMETHYL)PHENYL]-3-ISOXAZOLECARBOXAMIDE; AK174786; 5-[2,4-Dihydroxy-5-(1-Methylethyl)phenyl]-N-Ethyl-4-[4-(Morpholin-4-Ylmethyl)phenyl]isoxazole-3-Carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 135539077
  ChEBI ID: CHEMBL83656
  CAS Number: CAS 747412-49-3
  TTD Drug ID: DMTYXQF
  VARIDT Drug ID: DR00742

Molecule-Related Drug Atlas

Drug(s) Targeting Heat shock protein 90 alpha (HSP90A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cromoglicate	DM74LZK	Asthma	CA23	Approved	[6]
Amlexanox	DM0DQM5	Respiratory tract inflammation	CA07	Approved	[6]
BIIB-021	DMPAJ41	Breast cancer	2C60-2C65	Phase 2	[7]
KW-2478	DMJGL72	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
VER 50589	DMFLZPC	Breast cancer	2C60-2C65	Phase 2	[3]
Tanespimycin	DMNLQHK	Breast cancer	2C60-2C65	Phase 2	[9]
Efungumab	DMBHP56	Breast cancer	2C60-2C65	Phase 2	[10]
SNX-5422	DMIU0VP	Haematological malignancy	2B33.Y	Phase 1/2	[11]
PU3	DMJO0BP	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
Debio 0932	DMWP3G1	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]

Drug(s) Affected By Anterior gradient protein 2 homolog (AGR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[13]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[14]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[15]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[16]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[17]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[18]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[19]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[19]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[20]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[21]

Drug(s) Affected By Fibroblast growth factor 1 (FGF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[22]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[23]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[24]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[24]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[25]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[28]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[24]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[13]

Drug(s) Affected By ATP synthase subunit beta, mitochondrial (ATP5F1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[29]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[14]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[30]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[31]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[32]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[21]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[34]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[32]

Drug(s) Affected By Hepatocyte growth factor receptor (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[35]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[36]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[37]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[37]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[37]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[23]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[15]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[37]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[23]

Drug(s) Affected By Poly polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[22]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[39]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[40]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[41]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[42]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[43]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[42]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[44]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[45]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[46]

Drug(s) Affected By Mast/stem cell growth factor receptor Kit (KIT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[47]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[48]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[49]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[50]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[51]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[54]
Cholecalciferol	DMGU74E	Adult acute monocytic leukemia		Approved	[55]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[56]

Drug(s) Affected By S-formylglutathione hydrolase (ESD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[57]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[58]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[59]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[21]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[60]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[61]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[62]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[63]
DNCB	DMDTVYC	Immune System disease	4A01-4B41	Phase 2	[64]

Drug(s) Affected By Elongation factor 2 (EEF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[65]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[66]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[21]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[67]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[68]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[63]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[69]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[70]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[69]

Drug(s) Affected By Intron Large complex component GCFC2 (GCFC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[15]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[57]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[71]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[21]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[72]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[73]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[74]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[75]
Tanespimycin	DMNLQHK	Breast cancer	2C60-2C65	Phase 2	[4]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[76]

Drug(s) Affected By Proteasome subunit alpha type-1 (PSMA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[77]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[16]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[58]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[21]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[78]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[79]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[80]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[76]

Drug(s) Affected By M-phase inducer phosphatase 3 (CDC25C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[81]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[82]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[83]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[15]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[84]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[57]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[85]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[86]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[87]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[19]

Drug(s) Affected By Radixin (RDX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[57]
Haloperidol	DM96SE0	Delirium		Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[20]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[21]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[88]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[89]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[90]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[91]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[92]
Topotecan	DMP6G8T	Central nervous system neoplasm		Approved	[93]

Drug(s) Affected By Serpin H1 (SERPINH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[94]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[57]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[95]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[96]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[71]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[97]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[21]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[98]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[88]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[90]

Drug(s) Affected By Small ubiquitin-related modifier 3 (SUMO3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[99]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[99]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[72]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[100]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[101]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[76]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[102]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[103]

Drug(s) Affected By Peptidyl-prolyl cis-trans isomerase A (PPIA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[104]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[30]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[105]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[15]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[77]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[58]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[106]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[20]
Dihydroartemisinin	DMBXVMZ	Malaria	1F40-1F45	Approved	[107]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]

Drug(s) Affected By Echinoderm microtubule-associated protein-like 5 (EML5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[108]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[13]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[62]
Tanespimycin	DMNLQHK	Breast cancer	2C60-2C65	Phase 2	[4]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[109]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[110]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[111]

Drug(s) Affected By Interleukin enhancer-binding factor 3 (ILF3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[84]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[112]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[97]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[21]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[90]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[113]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[114]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[73]
Tamibarotene	DM3G74J	T-cell leukaemia	2A90	Phase 3	[112]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[115]

Drug(s) Affected By Eukaryotic translation initiation factor 3 subunit I (EIF3I)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[57]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[65]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[116]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[97]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[21]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[88]
Tanespimycin	DMNLQHK	Breast cancer	2C60-2C65	Phase 2	[4]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[117]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[76]

Drug(s) Affected By Phenylalanine--tRNA ligase beta subunit (FARSB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[14]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[57]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[97]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[21]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[78]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[61]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[88]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[118]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[14]

Drug(s) Affected By Protein PALS2 (PALS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[15]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[119]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[71]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[120]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[21]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[61]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[121]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[121]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[122]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[123]

Drug(s) Affected By Cingulin (CGN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[83]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[124]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[125]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[126]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[56]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[60]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[127]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[20]

Drug(s) Affected By Poly polymerase 2 (PARP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[128]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[105]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[58]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[19]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[19]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[129]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[71]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[59]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[90]

Drug(s) Affected By Hypoxia up-regulated protein 1 (HYOU1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[130]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[97]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[21]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[60]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[90]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[62]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[131]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[63]
Aminoglutethimide	DMWFHMZ	Cushing disease	5A70	Approved	[132]
Bicalutamide	DMZMSPF	Prostate cancer	2C82.0	Approved	[133]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Heat shock protein 90 alpha (HSP90A)	TT78R5H	HS90A_HUMAN	Inhibitor	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Anterior gradient protein 2 homolog (AGR2)	OTRRZT7W	AGR2_HUMAN	Gene/Protein Processing	[4]
ATP synthase subunit beta, mitochondrial (ATP5F1B)	OTLFZUQK	ATPB_HUMAN	Gene/Protein Processing	[4]
Cingulin (CGN)	OTBCQ8AQ	CING_HUMAN	Gene/Protein Processing	[4]
Echinoderm microtubule-associated protein-like 5 (EML5)	OT0EFCPB	EMAL5_HUMAN	Gene/Protein Processing	[4]
Elongation factor 2 (EEF2)	OTZ7SZ39	EF2_HUMAN	Gene/Protein Processing	[4]
Eukaryotic translation initiation factor 3 subunit I (EIF3I)	OTE07WND	EIF3I_HUMAN	Gene/Protein Processing	[4]
Fibroblast growth factor 1 (FGF1)	OT8I64X8	FGF1_HUMAN	Gene/Protein Processing	[4]
Hepatocyte growth factor receptor (MET)	OT7K55MU	MET_HUMAN	Gene/Protein Processing	[5]
Hypoxia up-regulated protein 1 (HYOU1)	OTBGBSOV	HYOU1_HUMAN	Gene/Protein Processing	[4]
Interleukin enhancer-binding factor 3 (ILF3)	OTKMZ5K5	ILF3_HUMAN	Gene/Protein Processing	[4]

References

• [1] ClinicalTrials.gov (NCT01854034) Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR. U.S. National Institutes of Health.
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027019)
• [3] Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
• [4] Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry. Cells. 2019 Jul 31;8(8):806. doi: 10.3390/cells8080806.
• [5] Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma. Cancer. 2013 Jan 15;119(2):293-303. doi: 10.1002/cncr.27743. Epub 2012 Jul 18.
• [6] Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41.
• [7] BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009 Apr;8(4):921-9.
• [8] Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J. 2012 Apr;2(4):e68.
• [9] Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs. 2009 Jun;18(6):861-8.
• [10] Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009 Nov;43(11):1818-23.
• [11] SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hema... Blood. 2009 Jan 22;113(4):846-55.
• [12] Clinical pipeline report, company report or official report of Debiopharm (2011).
• [13] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [14] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [15] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [16] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [17] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [18] Comparative effects of DHEA and DHT on gene expression in human LNCaP prostate cancer cells. Anticancer Res. 2006 Sep-Oct;26(5A):3205-15.
• [19] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [20] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [21] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [22] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [23] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [24] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [25] Aberrantly expressed genes in HaCaT keratinocytes chronically exposed to arsenic trioxide. Biomark Insights. 2011 Feb 8;6:7-16.
• [26] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [27] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [28] WNT7A/-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer. Oncogene. 2015 Jun;34(26):3452-62. doi: 10.1038/onc.2014.277. Epub 2014 Sep 1.
• [29] Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1. Mol Endocrinol. 2010 May;24(5):969-80. doi: 10.1210/me.2009-0148. Epub 2010 Mar 8.
• [30] Consequences of the natural retinoid/retinoid X receptor ligands action in human breast cancer MDA-MB-231 cell line: Focus on functional proteomics. Toxicol Lett. 2017 Nov 5;281:26-34. doi: 10.1016/j.toxlet.2017.09.001. Epub 2017 Sep 5.
• [31] Biotinylated quercetin as an intrinsic photoaffinity proteomics probe for the identification of quercetin target proteins. Bioorg Med Chem. 2011 Aug 15;19(16):4710-20. doi: 10.1016/j.bmc.2011.07.005. Epub 2011 Jul 13.
• [32] Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor co-activator-1 protein. Br J Pharmacol. 2010 Oct;161(4):771-81. doi: 10.1111/j.1476-5381.2010.00900.x.
• [33] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [34] Effects of acute ethanol treatment on NCCIT cells and NCCIT cell-derived embryoid bodies (EBs). Toxicol In Vitro. 2010 Sep;24(6):1696-704. doi: 10.1016/j.tiv.2010.05.017. Epub 2010 May 26.
• [35] ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
• [36] Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
• [37] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [38] All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. Cancer Lett. 2005 Jun 28;224(2):303-10. doi: 10.1016/j.canlet.2004.10.016. Epub 2004 Dec 8.
• [39] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [40] Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
• [41] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [42] The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
• [43] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [44] Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
• [45] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [46] Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
• [47] Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. Mol Cancer Ther. 2009 Jan;8(1):152-9. doi: 10.1158/1535-7163.MCT-08-0553.
• [48] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [49] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [50] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [51] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [52] [Demethylation effect of inhibitor As2O3 on expression of SHP-1 and C-kit genes in leukemia HL-60 cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Jun;21(3):613-6. doi: 10.7534/j.issn.1009-2137.2013.03.015.
• [53] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [54] Cardiac toxicity from ethanol exposure in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci. 2019 May 1;169(1):280-292.
• [55] Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med. 2010 Apr 12;207(4):731-50. doi: 10.1084/jem.20091488. Epub 2010 Apr 5.
• [56] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [57] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [58] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [59] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [60] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [61] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [62] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [63] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [64] Proteomic analysis of the cellular response to a potent sensitiser unveils the dynamics of haptenation in living cells. Toxicology. 2020 Dec 1;445:152603. doi: 10.1016/j.tox.2020.152603. Epub 2020 Sep 28.
• [65] Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells. J Proteome Res. 2009 Jun;8(6):3006-19.
• [66] Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. Toxicol Sci. 2011 Mar;120(1):109-22.
• [67] Effects of paclitaxel on proliferation and apoptosis in human acute myeloid leukemia HL-60 cells. Acta Pharmacol Sin. 2004 Mar;25(3):378-84.
• [68] Quantitative Assessment of Arsenite-Induced Perturbation of Ubiquitinated Proteome. Chem Res Toxicol. 2022 Sep 19;35(9):1589-1597. doi: 10.1021/acs.chemrestox.2c00197. Epub 2022 Aug 22.
• [69] Sumoylation of eukaryotic elongation factor 2 is vital for protein stability and anti-apoptotic activity in lung adenocarcinoma cells. Cancer Sci. 2011 Aug;102(8):1582-9. doi: 10.1111/j.1349-7006.2011.01975.x. Epub 2011 Jun 23.
• [70] Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. Br J Pharmacol. 2011 Apr;162(8):1743-56.
• [71] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [72] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [73] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [74] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [75] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [76] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [77] Synergistic effects of retinoic acid and tamoxifen on human breast cancer cells: proteomic characterization. Exp Cell Res. 2007 Jan 15;313(2):357-68. doi: 10.1016/j.yexcr.2006.10.016. Epub 2006 Oct 25.
• [78] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [79] Changes in composition and activities of 26S proteasomes under the action of doxorubicin--apoptosis inductor of erythroleukemic K562 cells. Cell Biol Int. 2007 Apr;31(4):338-48. doi: 10.1016/j.cellbi.2007.01.018. Epub 2007 Jan 21.
• [80] Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
• [81] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [82] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [83] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [84] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [85] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [86] Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 2000 Jun 1;60(11):3065-71.
• [87] Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 2006 Jul 1;66(13):6615-21. doi: 10.1158/0008-5472.CAN-05-4566.
• [88] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [89] The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28.
• [90] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [91] Gene expression data from acetaminophen-induced toxicity in human hepatic in vitro systems and clinical liver samples. Data Brief. 2016 Mar 26;7:1052-1057. doi: 10.1016/j.dib.2016.03.069. eCollection 2016 Jun.
• [92] Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer. BMC Genomics. 2006 Apr 3;7:68. doi: 10.1186/1471-2164-7-68.
• [93] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [94] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [95] Glucosamine-induced endoplasmic reticulum dysfunction is associated with accelerated atherosclerosis in a hyperglycemic mouse model. Diabetes. 2006 Jan;55(1):93-101.
• [96] Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9. Oncotarget. 2016 Dec 13;7(50):83359-83377.
• [97] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [98] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [99] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [100] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [101] Interindividual variation in gene expression responses and metabolite formation in acetaminophen-exposed primary human hepatocytes. Arch Toxicol. 2016 May;90(5):1103-15. doi: 10.1007/s00204-015-1545-2. Epub 2015 Jun 24.
• [102] Effect of endosulfan and bisphenol A on the expression of SUMO and UBC9. Drug Chem Toxicol. 2020 Nov;43(6):637-644. doi: 10.1080/01480545.2018.1526179. Epub 2018 Nov 14.
• [103] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [104] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [105] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [106] Protein profile in neuroblastoma cells incubated with S- and R-enantiomers of ibuprofen by iTRAQ-coupled 2-D LC-MS/MS analysis: possible action of induced proteins on Alzheimer's disease. Proteomics. 2008 Apr;8(8):1595-607. doi: 10.1002/pmic.200700556.
• [107] Untargeted Proteomics and Systems-Based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells. Chem Res Toxicol. 2015 Oct 19;28(10):1903-13. doi: 10.1021/acs.chemrestox.5b00105. Epub 2015 Sep 21.
• [108] Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
• [109] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [110] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [111] Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 2018 Apr;92(4):1453-1469.
• [112] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [113] Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569.
• [114] Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015 Apr 16;234(2):139-50.
• [115] Comparative proteomics reveals concordant and discordant biochemical effects of caffeine versus epigallocatechin-3-gallate in human endothelial cells. Toxicol Appl Pharmacol. 2019 Sep 1;378:114621. doi: 10.1016/j.taap.2019.114621. Epub 2019 Jun 10.
• [116] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [117] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [118] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [119] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [120] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [121] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [122] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [123] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [124] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [125] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [126] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [127] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [128] Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. J Med Chem. 2017 Feb 23;60(4):1262-1271. doi: 10.1021/acs.jmedchem.6b00990. Epub 2016 Dec 21.
• [129] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [130] Inter-laboratory comparison of human renal proximal tubule (HK-2) transcriptome alterations due to Cyclosporine A exposure and medium exhaustion. Toxicol In Vitro. 2009 Apr;23(3):486-99.
• [131] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [132] Proteomic profile of aminoglutethimide-induced apoptosis in HL-60 cells: role of myeloperoxidase and arylamine free radicals. Chem Biol Interact. 2015 Sep 5;239:129-38.
• [133] Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines. J Pharm Pharmacol. 2005 Jan;57(1):83-92.